Mr. Gadi Levin reports

VAXIL BIO PROPOSED REVERSE TAKEOVER WITH COPPER BULLET TERMINATED AND UPDATE OF RESEARCH ACTIVITIES

Further to Vaxil Bio Ltd.'s press release from Jan. 10, 2024, with Copper Bullet Mines Inc. (CBMI), the company has received a notice of termination of the letter of intent between the company and CBMI.

The company will continue to actively explore other strategic options for maximizing shareholder value, including the continued development of Vaxil's existing assets.

To this end, the company is pleased to advise that the work performed by the company together with Prof. Ayelet David, from Ben-Gurion University of the Negev (BGU), which demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC) has now been published and is available for review in the journal Nano.

The company has an exclusive worldwide licence agreement for the development and commercialization of this targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the company will pay BGU a royalty on sales.

About Vaxil Bio Ltd.

Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA (Food and Drug Administration) and EMA. The company aims to continue to develop ImMucin, a COVID-19 and a tuberculosis vaccine/treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit, Vaxil's proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by educating or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil's mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.

We seek Safe Harbor.